GEN-MKT-18-7897-A
Jun 1, 2017 | Blogs, Technology | 0 comments
When you’re in the process of moving your lab, across the corridor or to another country, there’s a lot to think about. Adding to the stress, there’s not always a lot of time to plan, or budget allocated for the process, especially in the case of unexpected urgent maintenance work.Getting your instruments up and running again as quickly and smoothly as possible is your top priority. Let’s face it; every lab could do without the downtime!
That’s where SCIEX Professional Relocation Services could help you with the whole process.
With your move taken care of, now might be a good time to think about:
“Our instrument rooms required urgent maintenance works for a 2-week period. The SCIEX team of Field Service Engineers were on hand the week before the works to decommission and securely package our instruments, and to setup and recommission our equipment afterward. The whole process went smoothly, and our equipment was up and running again in no time thanks to the diligence of the SCIEX team.” – Dr. Julie Brazzatti, Stoller Biomarker Discovery Centre, The University of Manchester
Are you planning a relocation in the near future? Find out more about Professional Relocation Services , or talk to your SCIEX representative.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
Posted by
You must be logged in to post a comment.
Share this post with your network